Hospital
Doctors' Hospital of Williamsburg
Doctors' Hospital of Williamsburg was paid $11.99M by Medicaid between Jan 2018 and Dec 2024, across 164 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoDOCTORS' HOSPITAL OF WILLIAMSBURG
WILLIAMSBURG, VA 23185
WILLIAMSBURG, VA 23185
33aNPI1275893307assigned 05/23/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.99M
24GClaims308,262
24DCodes billed164
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#45 of 80
Median peer was paid$14.69M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official AUSTIN, WALTER controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,094 | $472K | |
| 2019 | 29,829 | $926K | |
| 2020 | 36,325 | $1.35M | |
| 2021 | 52,569 | $1.83M | |
| 2022 | 49,779 | $1.80M | |
| 2023 | 65,693 | $2.80M | |
| 2024incomplete | 55,973 | $2.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 19,248 | 16,661 | $3.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 12,935 | 10,956 | $2.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 7,272 | 5,312 | $1.98M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.4% | 13,402 | 4,197 | $642K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 3,462 | 3,152 | $484K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,251 | 2,011 | $426K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 2,823 | 2,296 | $366K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 1,970 | 1,741 | $362K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 662 | 631 | $249K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 1,931 | 1,593 | $234K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,241 | 1,590 | $179K |
| 97162 | 1.3% | 1,116 | 1,036 | $156K |
152 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 824 | $146K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 1,686 | $146K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 3,232 | $141K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 871 | $140K |
| G0378 | Hospital observation service, per hour | <1% | 597 | $80K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 374 | $77K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,778 | $74K |
| 97161 | <1% | 395 | $63K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,657 | $61K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,058 | $61K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,391 | $46K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 107 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 11,841 | $38K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 99 | $32K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 140 | $24K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 88 | $23K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 214 | $23K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 101 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,734 | $17K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 83 | $17K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 27 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,189 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,291 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 236 | $11K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $9K |
| 72141 | <1% | 34 | $8K | |
| 80047 | <1% | 2,442 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $8K |
| 76942 | <1% | 352 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,164 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,840 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,373 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 54 | $5K |
| 84484 | <1% | 5,584 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,037 | $4K |
| 64450 | <1% | 30 | $4K | |
| 20610 | <1% | 21 | $4K | |
| 73630 | <1% | 289 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,875 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,230 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,292 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 780 | $3K |
| J3490 | Unclassified drugs | <1% | 7,687 | $3K |
| 97750 | <1% | 128 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 214 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,897 | $3K |
| 83880 | <1% | 476 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 95 | $3K |
| 97163 | <1% | 14 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 723 | $2K |
| 87510 | <1% | 400 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,025 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,211 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 898 | $2K |
| 85379 | <1% | 638 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,229 | $2K |
| 73610 | <1% | 177 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 489 | $1K |
| 73030 | <1% | 127 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 26 | $1K |
| 73562 | <1% | 73 | $1K | |
| 83605 | <1% | 2,328 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,235 | $1K |
| 87040 | <1% | 218 | $1K | |
| 87660 | <1% | 400 | $1K | |
| 85652 | <1% | 329 | $967.86 | |
| 90715 | <1% | 42 | $925.67 | |
| 93971 | <1% | 16 | $886.33 | |
| 81001 | <1% | 8,643 | $867.03 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,451 | $851.58 |
| 94726 | <1% | 32 | $767.34 | |
| 81025 | <1% | 5,257 | $760.82 | |
| 82947 | <1% | 4,167 | $633.07 | |
| 80076 | <1% | 212 | $611.21 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,167 | $551.10 |
| 86885 | <1% | 214 | $542.13 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,673 | $538.59 |
| 73130 | <1% | 82 | $530.38 | |
| 97116 | <1% | 23 | $492.17 | |
| 86900 | <1% | 392 | $474.11 | |
| 83735 | <1% | 2,654 | $452.17 | |
| A9150 | Non-prescription drugs | <1% | 24,343 | $416.53 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,412 | $367.90 |
| 94729 | <1% | 32 | $329.73 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 754 | $314.26 |
| 86901 | <1% | 392 | $306.36 | |
| 86140 | <1% | 191 | $298.29 | |
| 73502 | <1% | 27 | $289.13 | |
| 97802 | <1% | 12 | $272.88 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,088 | $271.92 |
| 85610 | <1% | 766 | $270.94 | |
| 82077 | <1% | 1,823 | $270.00 | |
| 85014 | <1% | 2,614 | $264.27 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 219 | $260.01 |
| 83690 | <1% | 4,090 | $257.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,745 | $207.01 |
| 87077 | <1% | 1,052 | $185.11 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,268 | $177.19 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,883 | $152.01 |
| 81003 | <1% | 688 | $150.33 | |
| 86756 | <1% | 199 | $148.48 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 57 | $146.28 |
| 87081 | <1% | 991 | $144.69 | |
| 73560 | <1% | 124 | $124.20 | |
| 73110 | <1% | 13 | $122.06 | |
| 74018 | <1% | 12 | $118.54 | |
| 87186 | <1% | 740 | $112.31 | |
| 84703 | <1% | 1,168 | $109.17 | |
| 87430 | <1% | 1,190 | $73.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 959 | $71.60 |
| 36592 | <1% | 175 | $64.42 | |
| 80061 | Lipid panel | <1% | 16 | $60.28 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 790 | $55.44 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 579 | $47.14 |
| 87480 | <1% | 400 | $46.71 | |
| 81002 | <1% | 1,231 | $33.49 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 299 | $29.67 |
| 00813 | <1% | 98 | $24.86 | |
| 96376 | <1% | 1,151 | $18.46 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,983 | $15.16 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 107 | $12.20 |
| 84100 | <1% | 68 | $10.88 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 73 | $8.55 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 558 | $8.41 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 144 | $6.25 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 462 | $3.35 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 42 | $2.99 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 17 | $2.64 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 70 | $1.44 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 39 | $0.92 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 57 | $0.72 |
| 85730 | <1% | 14 | $0.40 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 54 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 190 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 199 | $0.00 |
| 80179 | 0% | 16 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 206 | $0.00 |
| 80143 | 0% | 16 | $0.00 | |
| 84702 | 0% | 14 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 89 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 25 | $0.00 |
| 84295 | 0% | 22 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 772 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,242 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 107 | $0.00 |
| A6454 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 12 | $0.00 |
| 88342 | 0% | 20 | $0.00 | |
| 82330 | 0% | 22 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 144 | $0.00 |
| 82803 | 0% | 14 | $0.00 | |
| 84132 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAUSTIN, WALTER (SR VICE PRESIDENT/CFO)
| Provider | Location | Paid |
|---|---|---|
| Riverside Hospital INC | Newport News, VA | $136.80M |
| Shore Health Services INC. | Onancock, VA | $24.72M |
| Riverside Middle Peninsula Hospital INC | Gloucester, VA | $19.02M |
| Riverside Hospital INC | Newport News, VA | $4.48M |
| Patrick Henry Hospital, INC. | Newport News, VA | $1.52M |
| Shore Health Services, INC | Accomac, VA | $1.31M |
| Riverside Hospice and Homecare Services LLC | Warsaw, VA | $438K |
| Riverside Hospital INC | Newport News, VA | $412K |
| Riverside Middle Peninsula Hospital INC | Gloucester, VA | $37K |
| Riverside Hospital, INC | Newport News, VA | $6K |
| Patrick Henry Hospital, INC. | West Point, VA | $4K |
| Shore Health Services INC | Accomac, VA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.